Infection and Drug Resistance (Jan 2016)
A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections
Abstract
Aditya K Gupta,1,2 Deanne Daigle2 1Department of Medicine, University of Toronto School of Medicine, Toronto, 2Dermatology, Mediprobe Research Inc., London, ON, Canada Abstract: Luliconazole is a novel imidazole derivative, which has demonstrated in vitro efficacy against dermatophytes and Candida. The results from Phase III trials show that luliconazole 1% cream applied once daily for 2 weeks successfully resolved the clinical signs and symptoms as well as eradicated the pathologic fungi, which cause tinea pedis. A 1-week treatment with luliconazole 1% cream also produced favorable clinical and mycological results in clinical trials for tinea corporis and tinea cruris. Across trials, adverse events consisted mainly of localized reactions following application. The development of a new antifungal agent is timely due to mounting resistance among existing treatments. Because luliconazole requires a short duration of treatment, it may assist in reducing disease recurrence as a result of patient nonadherence. Keywords: antifungal, dermatophyte, athlete's foot, tinea cruris, tinea corporis, imidazole
